Wave Life Sciences Ltd (WVE) - Total Assets
Based on the latest financial reports, Wave Life Sciences Ltd (WVE) holds total assets worth $583.54 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Wave Life Sciences Ltd - Total Assets Trend (2013–2025)
This chart illustrates how Wave Life Sciences Ltd's total assets have evolved over time, based on quarterly financial data. Also see Wave Life Sciences Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Wave Life Sciences Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Wave Life Sciences Ltd's total assets of $583.54 Million consist of 96.3% current assets and 3.7% non-current assets. Review WVE total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 94.3% |
| Accounts Receivable | $1.28 Million | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Wave Life Sciences Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Wave Life Sciences Ltd share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Wave Life Sciences Ltd's current assets represent 96.3% of total assets in 2025, an increase from 33.5% in 2013.
- Cash Position: Cash and equivalents constituted 94.3% of total assets in 2025, up from 18.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
Wave Life Sciences Ltd Competitors by Total Assets
Key competitors of Wave Life Sciences Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Wave Life Sciences Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.26 | 2.95 | 3.41 |
| Quick Ratio | 11.26 | 2.95 | 3.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $511.44 Million | $170.61 Million | $112.71 Million |
Wave Life Sciences Ltd - Advanced Valuation Insights
This section examines the relationship between Wave Life Sciences Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.81 |
| Latest Market Cap to Assets Ratio | 1.34 |
| Asset Growth Rate (YoY) | 81.3% |
| Total Assets | $638.50 Million |
| Market Capitalization | $858.11 Million USD |
Valuation Analysis
Above Book Valuation: The market values Wave Life Sciences Ltd's assets above their book value (1.34x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Wave Life Sciences Ltd's assets grew by 81.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Wave Life Sciences Ltd (2013–2025)
The table below shows the annual total assets of Wave Life Sciences Ltd from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $638.50 Million | +81.29% |
| 2024-12-31 | $352.21 Million | +28.10% |
| 2023-12-31 | $274.95 Million | +87.82% |
| 2022-12-31 | $146.39 Million | -29.28% |
| 2021-12-31 | $207.01 Million | -25.87% |
| 2020-12-31 | $279.24 Million | -1.76% |
| 2019-12-31 | $284.25 Million | -3.95% |
| 2018-12-31 | $295.94 Million | +62.74% |
| 2017-12-31 | $181.84 Million | +10.33% |
| 2016-12-31 | $164.81 Million | -0.37% |
| 2015-12-31 | $165.42 Million | +5530.50% |
| 2014-12-31 | $2.94 Million | +26.47% |
| 2013-12-31 | $2.32 Million | -- |
About Wave Life Sciences Ltd
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent diso… Read more